# Safety and Relative Bioavailability of BIBF 1120 Soft Gelatine Capsules Charge 1, BIBF 1120 Soft Gelatine Capsules Charge 2 and BIBF 1120 Drinking Solution in Healthy Male Volunteers

> **NCT02182193** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 54 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BIBF 1120 capsules charge 1
- **DRUG:** BIBF 1120 capsules charge 2
- **DRUG:** BIBF 1120 drinking solution

## Key facts

- **NCT ID:** NCT02182193
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2006-11
- **Final completion:** —
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2014-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02182193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02182193, "Safety and Relative Bioavailability of BIBF 1120 Soft Gelatine Capsules Charge 1, BIBF 1120 Soft Gelatine Capsules Charge 2 and BIBF 1120 Drinking Solution in Healthy Male Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02182193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*